Assessment of the Effectiveness of OLMETEC® and OLMETEC PLUS® for Treatment of Hypertension in Stage I and II Patients (Study P05254)(COMPLETED)

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the efficiency of Olmesartan medoxomile (OLMETEC®) alone or in combination with hydrochlorothiazide (OLMETEC PLUS®) in the reduction of arterial blood pressure in patients with light to moderate hypertension, and to evaluate the percentage of patients that reach treatment goals using this antihypertensive regimen.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Schering-Plough
• Treatments: Hydrochlorothiazide; Olmesartan; Olmesartan Medoxomil

Criteria

Inclusion Criteria:

• Men or women 18 years of age or older

• Essential arterial hypertension Stade I and II according to JNC VII

• Signature of Informed Consent

Exclusion Criteria:

• Secondary arterial hypertension

• Pregnant woman or during lactancy

• Recent cardiovascular disease, as heart attack, unstable angina, or procedures of coronary revascularization on the previous six months.

• Acute Coronary Failure Syndrome on the previous six months.

• Chronic Ischemic Cardiopathy Treatment.

• Cerebral Vascular Disease on the previous six months.

• Alcoholism Story or use of drugs on the two previous years.

• Hepatic Disease Story

• Chronic Renal Failure defined by a serumal creatinine higher than 2mg/dl

• Albuminuria higher than 1gr.

• Known Allergy to blockers of angiotensine II receptors.

• Neoplasmic Malignant Disease included leukemia and the lymphoma (Skin basocellular cancer is not included)

• Auto Immune Disorders as systemic erythematosus lupus.

• Non attachment to medical treatments history.

• Patients sharing some clinical investigation essay on the last 3 months.

• Congestive heart failure under previous treatment with ECA inhibitors.

• Allergy to thiazidic diuretics.

• Angioedema History

• Use of drugs that affect potassium secretion, as diuretic savers of potassium, angiotensine enzyme inhibitor, betablockers, non-steroid anti-inflammatory drugs.

• Potassium consumption orally